Ubmmg,  you and Mabel have been more on the "right side" of this story for the past year,  and bulls like myself "early and wrong".  

 

 

But there are a few "catalysts" in the very short term horizon . . . .. some in weeks . . . . some in less than two months away . . . . that could absolutely draw some new money into this stock . . . .  and with one or two sizable institutional buyers . . . .  the stock could easily trade over $3 . . . . .  and even $4 by December . . .. . "if" Helen delivers the bacon !   

 

 

Here are the potential catalysts :

 

 

1)   Helen has said a few times that they are trying to "partner" AG019.  There are some who think a "deal" is almost "done" . . ..  that they are just waiting for the FDA to approve the phase 3 trial format . . . . and then a deal will be announced. 

 

 

(Please note : the effort to partner this asset has been going on for months and months . . . . . not unlike the sale of Transova which she telegraphed in January and delivered the first announcement seven months later and it didn't "close" for a few more months . . . .  these things take time.)

 

 

I'm not looking for a huge upfront payment.  Maybe PGEN gets $25M and a royalty.  But this would represent the first "third party validation" of PGEN's IP since Merck years and years ago.  

 

 

2)  In her fireside chat Helen said she was hoping to have a "regulatory path forward from the FDA for both PRGN-2012 and PRGN 2009 by year end".  Hope springs eternal . . . .  and Helen can't make the FDA "speed up" anything . . . . but those who know Helen will confirm that she isn't a blow hard like Kirk . . . . .  she has consistently tried to "under promise and over deliver" . . . . . . and when she says that the data will be "compelling and comprehensive" for PRGN-2012,  . . . . .  with a great safety profile . . . .. a path for an approval after an expanded phase 2 is "possible".  And that expansion is underway now.

 

 

 

3). The PRGN-2009 trial has been going almost two years.   Last November,  almost a year ago,  they said the enrollment in the phase 2 study was underway.   For Helen to talk about expecting a "regulatory path forward" for PRGN-2009 perhaps by year end has to be a possible "clue" that Helen thinks the data is good.  Look for an update in the November Investor presentation.

 

 

4). Another nationally recognized cancer institute  . . . . or two . . . . . could announce that they are starting to use the UltraPorator.  This will be more proof that the company really has a cheap,  overnight, manufacturing capability  . . . . . . . something that's quite rare in the space.  An expansion of test sites will help drive the data collection process forward.

 

 

 

5).  ASH submissions are due in about two weeks.  Last year Dr. Sallman was awarded an oral presentation.  Could it happen again ?  We'll know in early November but re-read the December 13,  2021 press release.  The data was very good . . . .  the sample size was too small . . . .. let's see how things have progressed.  Real progress could be another reason why the company might attract some institutional money to the stock.

 

 

This company has a HORRIBLE history thanks in large part to the Carnival Barker.  There is no meaningful institutional "sponsorship" of the stock.  If some institutional money starts to come into this name . . . . .  this will be an important development and we should see much better prices.